|
Source | Active substance/extract | Effective concentration | Cancer type | Target gene |
|
Actinidia callosa var. callosa | Ethyl acetate fraction of Actinidia callosa var. callosa (EAAC) | IC50: 73.3 and 92.7 μg/ml for 24 h treatment | Hepatoma | AKT1, MAPK1, MMP2, MMP9, PIK3CD, TIMP2 |
Aegle marmelos | Beta-caryophyllene and caryophyllene oxide fractions of Aegle marmelos extract | Maximum inhibition: 50 μg/ml for 24 h treatment | Lymphoma; neuroblastoma | ATM, BAK1, BAX, BCL2, CASP8, CASP9, MDM2, PTGS2 |
Allium sativum (garlic) | Allicin | Maximum inhibition: 90 μg/ml for 24 h treatment | Glioblastoma | BAX, BCL2 |
Allium sativum (garlic) | N-Benzyl-N-methyldecan-1-amine (NBNMA) | Maximum inhibition: 50 μg/ml for 24 h treatment | Leukemia | BAD, BAX, BCL2, BCL2L1, BIRC2, CASP3, CASP8, CASP9, CDK2, CDKN1A, XIAP |
Aloe vera (Barbados aloe) | Aloin (AL) | IC50: 10 μmol/l for 72 h treatment | Colorectal cancer | BCL2L1, MYC, STAT3 |
Anacardium occidentale (cashews) | Cardanol monoene (CM) extracted from cashew nut shell liquid (CNSL) | IC50: (24 h); (48 h) | Melanoma | BAX, BCL2, TP53, CASP3, PARP1 |
Annona muricata | Ethyl acetate extract of Annona muricata leaves (EEAM) | IC50: (HT-29); (HCT-116) for 24 h treatment | Colon cancer | CASP3, CASP7, CASP8, CASP9, BAX, BCL2 |
Arachis hypogaea (peanuts) | Resveratrol | IC50: (MCF-7); (HeLa) for 72 h treatment | Breast cancer; cervical cancer | CDK4, CDKN1A, MAPK3, TP53 |
Arachis hypogaea (peanuts) | Peanut skin procyanidins (PSP) | IC50: 48.57 μg/ml for 24 h treatment | Prostate cancer | BAX, BCL2, CASP3, TP53 |
Basella rubra (spinach) | Natural antioxidants (NAOs) from spinach extract | MIC: 3.2 mg/ml for 24 h treatment | Prostate cancer | CDK2, CDKN1A, E2F1, RB1, RBL1 |
Black pepper | Piperine | IC50: to for 72 h treatment | Colon cancer | AKT1, BIRC5, CCND1, CCND3, CDKN1A, CDKN1B, MAPK8 |
Black soybean | Black soybean extract | IC50: 3.69 mg/ml for 72 h treatment | Gastric cancer | BAX, BCL2, CASP3 |
Brassica spp. vegetables (cabbage, cauliflower, and brussels sprouts) | Indole-3-carbinol (I3C) | Maximum inhibition: 50 μM for 24 h treatment | Acute myeloid leukemia (AML); leukemia | AKT1, BCL2, BIRC2, BIRC5, CCND1, MMP9, NFKB1, NOS2, PTGS2, TNF, TRAF1, XIAP |
Castanea (chestnut) | Ethanol extracts of raw chestnut (RCE) | Maximum inhibition: 200 μg/ml for 24 h treatment | Gastric cancer | ASP3, CASP7, CASP8, FASLG, HLA-DRB1,PARP1, TNFSF10, XIAP |
Citrus aurantium | Flavonoids | IC50: 99 μg/ml for 24 h treatment | Gastric cancer | CASP3, CCNB1, CDK1, PARP1 |
Curcuma longa (turmeric) | Curcumin | Maximum inhibition: 25 μmol/l for 24 h treatment | Bladder cancer | NFKB1, PTGS2 |
Curcuma longa (turmeric) | Curcumin | IC50: 11 to 46 μM (72 h) | Pancreatic cancer | CXCL8, NFKB1, PTGS2 |
Curcuma longa (turmeric) | Curcumin | Maximum inhibition: 50 μM for 24 h treatment | Thyroid cancer | SMAD2, SMAD3, TGFB1 |
Daphne genkwa | Yuanhuadine | Maximum inhibition: 32 nM for 72 h treatment | Lung cancer | AKT1, CDK2, CDK4, CDKN1A, MYC |
Ipomoea batatas (sweet potato) | Sporamin | Maximum inhibition: 100 μM for 72 h treatment | Pancreatic cancer | BAX, BCL2, BCL2L1, NFKB1 |
Juglans mandshruica (Manchurian walnut) | Juglanin | IC50: 20.07 to 29.13 μM for 24 h treatment | Breast cancer | BAD, BAX, BCL2, CASP3, CASP8, CASP9, CDC25C, CDK1, CDKN1B, CHEK2 |
Juglans mandshruica (Manchurian walnut) | Juglone | IC50: 8 μM for 24 h treatment | Leukemia | AKT1, CASP3, MTOR, PIK3CD |
Lebanese Daucus carota (wild carrot) | Daucus carota oil extract (DCOE) | IC50: to for 48 h treatment | Skin Cancer | AKT1, BCl2, BAX |
Naematoloma sublateritium (hazel mushroom) | Hexane fraction of N. sublateritium extract (HFNS) | IC50: 200 μg/ml for 24 h treatment | Breast Cancer | JUN, MAPK14, MAPK8, MAPK9, MMP9, NFKB1, SERPINE1, TIMP2 |
Pulsatilla koreana | Pulsatilla koreana extract (PKE) | IC50: 120 to 140 μg/ml for 24 h treatment | Thyroid cancer | BAX, BCL2, CASP3, PARP1 |
Red sorghum bran | 3-Deoxyanthocyanidins | IC50: 300 μg/ml for 24 h treatment | Breast Cancer | BCL2, TP53 |
Sanguinaria canadensis (bloodroot) | Sanguinarine | IC50: 1 μM; maximum inhibition: 2 μM for 24 h treatment | Oral cancer | AKT1, CASP3, CASP9, PIK3CD |
|